Skip to main content
. 2022 Aug 23;37(1):2265–2282. doi: 10.1080/14756366.2022.2104841

Figure 8.

Figure 8.

Superimposition of the co-crystallised (blue) and the docking pose (pink) of erlotinib in the EGFR (A) and sorafenib in the VEGFR-2 (B) binding sites.